Ascenion’s portfolio company OMEICOS, a spin-off from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, has received further funding of approximately EUR 1.7 million from the German Federal Ministry of Education and Research (BMBF). Together with matching funds provided by the company, the proceeds will help OMEICOS attain its main research and development objectives. These include advancing its lead compound against atrial fibrillation towards clinical development, further investigating its mode of action and exploring the feasibility of its technology platform for additional indications. Ascenion’s coaching programme, the Spinnovator, supported OMEICOS from the beginning.
Earlier this year, the company had raised EUR 6.2 million in a series A financing round, which included a first tranche from the Spinnovator programme of EUR 0.55 million.
Further information: Press release from OMEICOS